Filing Analysis
Enanta Pharmaceuticals announced positive topline data from its Phase 2 pediatric study of zelicapavir for the treatment of respiratory syncytial virus (RSV). The results demonstrated a favorable safety profile and significant antiviral activity, particularly in patients treated early after symptom onset.
🚩 Red Flags
- One serious adverse event (SAE) in the zelicapavir group (community-acquired pneumonia), though deemed not treatment-related by investigators.
- Use of exploratory symptom tools (ReSViNET and RESOLVE-P) due to lack of validated regulatory tools for pediatric RSV, which may complicate future regulatory filings.
📋 Key Facts
- Phase 2 study was randomized, double-blind, dose-ranging, placebo-controlled involving 96 patients (70 zelicapavir, 26 placebo).
- Zelicapavir demonstrated a favorable safety profile; no AEs led to treatment discontinuation or withdrawal.
- Primary efficacy: Viral load decline peaked at 0.7 log on Day 9 vs. placebo in the overall population.
- Subgroup analysis: Patients randomized within 3 days of symptom onset (40% of study) showed a viral load decline of 0.9 log at Day 3 and 1.2 log at Day 5 vs. placebo.
- Dosing selected for future use: 5 mg/kg for age ≥ 28 days to <12 months; 7.5 mg/kg for age ≥12 months to ≤36 months.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly and annual financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 25, 2024
- Reporting period: Fiscal quarter and year-ended September 30, 2024
- The filing incorporates a press release (Exhibit 99.1) by reference.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended June 30, 2024.
📋 Key Facts
- Reporting period: Fiscal quarter ended June 30, 2024.
- Filing date: August 5, 2024.
- The filing incorporates a press release (Exhibit 99.1) by reference regarding results of operations and financial condition.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its quarterly earnings press release for the fiscal quarter ended March 31, 2024.
📋 Key Facts
- Report date: May 6, 2024
- Reporting period: Fiscal quarter ended March 31, 2024
- The filing serves to incorporate the company's press release via Exhibit 99.1.
Enanta Pharmaceuticals, Inc. reported the results of its Annual Meeting held on March 6, 2024. Stockholders approved an amendment to the 2019 Equity Incentive Plan and re-elected three Class II directors.
📋 Key Facts
- Stockholders approved increasing the number of shares reserved under the 2019 Equity Incentive Plan by 975,000 shares (Proposal No. 2).
- Three Class II Directors (Yujiro S. Hata, Kristine Peterson, and Terry C. Vance) were re-elected to serve until the 2027 Annual Meeting.
- The advisory 'say-on-pay' vote regarding executive compensation was approved by stockholders.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the 2024 fiscal year.
Enanta Pharmaceuticals, Inc. filed an 8-K to furnish its press release regarding financial results for the fiscal quarter ended December 31, 2023.
📋 Key Facts
- Reporting period: Fiscal quarter ended December 31, 2023.
- Filing date: February 7, 2024.
- The filing incorporates a press release (Exhibit 99.1) by reference.